2018
DOI: 10.1007/s10120-018-0794-1
|View full text |Cite
|
Sign up to set email alerts
|

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11

Abstract: ClinicalTrials.gov Identifier: NCT02527785.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
7
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 6 publications
(9 citation statements)
references
References 25 publications
2
7
0
Order By: Relevance
“…found that neutropenia, diarrhoea, and nausea were also the most frequent. Similar results were observed by Kim et al . and Ziętarska et al .…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…found that neutropenia, diarrhoea, and nausea were also the most frequent. Similar results were observed by Kim et al . and Ziętarska et al .…”
Section: Discussionsupporting
confidence: 92%
“…In a study with colorectal cancer patients undergoing treatment with a 5-flurouracil (5-FU)/leucovorin protocol, Prado et al 8 found that neutropenia, diarrhoea, and nausea were also the most frequent. Similar results were observed by Kim et al 42 and Ziętarska et al 43 Regarding haematological toxicities, there was no significant difference in the incidence of neutropenia, anaemia, creatinine, and thrombocytopenia toxicities between the sarcopenic or non-sarcopenic and the cachetic or non-cachetic patients at baseline. Miyata et al 5 also did not find a significant difference in patients during neoadjuvant chemotherapy for oesophageal cancer.…”
Section: Discussionsupporting
confidence: 88%
“… 2 , 3 Moreover, more than 50% of GC patients progress to an advanced stage with dismal prognosis. 4 , 5 The treatment of patients with locally advanced and metastatic disease is currently based on systemic therapy or palliative supportive care with a median overall survival of 1 year. 6 The targeted agent for human epidermal growth factor receptor 2 (HER2), trastuzumab, has been used with modest efficacy for advanced disease in HER2 + patients, which accounts for less than 20% of patients with gastric tumors.…”
Section: Introductionmentioning
confidence: 99%
“…During validation, WFO yielded a high concordance rate and multidisciplinary team approaches in medical oncology, including for breast [4–6], colon [7, 8], lung [7], and cervical [9] cancer. According to report conducted at MSKCC in the United States (US), the WFO-physician concordance rate was > 90% in 103 patients with nonmetastatic breast cancer [4–6].…”
Section: Introductionmentioning
confidence: 99%